JPMorgan Adjusts Price Target on HealthEquity to $56 From $82, Maintains Overweight Rating
© MT Newswires 2021
All news about HEALTHEQUITY, INC. |
|
|
|
Analyst Recommendations on HEALTHEQUITY, INC. |
|
|
| |
|
Sales 2023 |
826 M
-
-
|
Net income 2023 |
-53,7 M
-
-
|
Net cash 2023 |
106 M
-
-
|
P/E ratio 2023 |
-91,3x |
Yield 2023 |
- |
|
Capitalization |
4 866 M
4 866 M
-
|
EV / Sales 2023 |
5,76x |
Capi. / Sales 2024 |
5,38x |
Nbr of Employees |
3 702 |
Free-Float |
- |
|
|
Duration :
Period :
|
 |
|
Technical analysis trends HEALTHEQUITY, INC.
| Short Term | Mid-Term | Long Term | Trends | Bearish | Bullish | Neutral |
Income Statement Evolution
|
Mean consensus |
BUY |
Number of Analysts |
12 |
Last Close Price |
57,68 $ |
Average target price |
75,92 $ |
Spread / Average Target |
31,6% |
|